Theseus Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Theseus Pharmaceuticals's earnings have been declining at an average annual rate of -49.7%, while the Pharmaceuticals industry saw earnings growing at 6.5% annually.
Key information
-49.7%
Earnings growth rate
113.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -25.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Theseus Pharmaceuticals: Biotech Buyout Remains Attractive At $4.06 Because Of 2-Part CVR
Feb 01Theseus Pharmaceuticals (NASDAQ:THRX) Is In A Good Position To Deliver On Growth Plans
Aug 18
Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth
May 05Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth
Dec 07Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line
Aug 11Here's Why We're Not Too Worried About Theseus Pharmaceuticals' (NASDAQ:THRX) Cash Burn Situation
Apr 22Revenue & Expenses Breakdown
How Theseus Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -57 | 19 | 47 |
| 30 Jun 23 | 0 | -58 | 19 | 47 |
| 31 Mar 23 | 0 | -55 | 19 | 42 |
| 31 Dec 22 | 0 | -51 | 18 | 36 |
| 30 Sep 22 | 0 | -46 | 17 | 30 |
| 30 Jun 22 | 0 | -38 | 15 | 24 |
| 31 Mar 22 | 0 | -33 | 12 | 21 |
| 31 Dec 21 | 0 | -27 | 9 | 18 |
| 30 Sep 21 | 0 | -22 | 6 | 16 |
| 30 Jun 21 | 0 | -16 | 4 | 12 |
| 31 Mar 21 | 0 | -13 | 1 | 9 |
| 31 Dec 20 | 0 | -12 | 1 | 6 |
Quality Earnings: THRX is currently unprofitable.
Growing Profit Margin: THRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: THRX is unprofitable, and losses have increased over the past 5 years at a rate of 49.7% per year.
Accelerating Growth: Unable to compare THRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: THRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10.9%).
Return on Equity
High ROE: THRX has a negative Return on Equity (-25.21%), as it is currently unprofitable.